Soleno Therapeutics, Inc. (SLNO)
May 18, 2026 - SLNO was delisted (reason: acquired by NBIX)
53.01
0.00 (0.00%)
Inactive · Last trade price on May 15, 2026
Soleno Therapeutics Employees
Soleno Therapeutics had 182 employees as of December 31, 2025. The number of employees increased by 90 or 97.83% compared to the previous year.
Employees
182
Change
90
Growth
97.83%
Revenue / Employee
$1,565,978
Profits / Employee
$525,418
Market Cap
2.76B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 182 | 90 | 97.83% |
| Sep 30, 2025 | 152 | 60 | 65.22% |
| Jun 30, 2025 | 133 | - | - |
| Mar 31, 2025 | 115 | 82 | 248.48% |
| Dec 31, 2024 | 92 | 59 | 178.79% |
| Dec 31, 2023 | 33 | 8 | 32.00% |
| Dec 31, 2022 | 25 | 5 | 25.00% |
| Dec 31, 2021 | 20 | 3 | 17.65% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
SLNO News
- 5 weeks ago - Folia Health Launches “BRAVE-PWS” Study to Better Understand the Real-World Experience of Prader-Willi Syndrome Caregivers - GlobeNewsWire
- 5 weeks ago - Are TERN, SLNO, WSR Obtaining Fair Deals for their Shareholders? - PRNewsWire
- 6 weeks ago - SOLENO THERAPEUTICS, INC. (SLNO) DEADLINE ALERT Bernstein Liebhard LLP Reminds Soleno Therapeutics, Inc. Investors of Upcoming Deadline - GlobeNewsWire
- 6 weeks ago - Soleno withdraws EU rare disease drug application ahead of Neurocrine takeover - Reuters
- 6 weeks ago - Neurocrine to Buy Soleno for $2.9 Billion - WSJ
- 6 weeks ago - Neurocrine to buy Soleno Therapeutics for $2.9 billion - Reuters
- 6 weeks ago - Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio - PRNewsWire
- 7 weeks ago - SLNO Stockholders Have Rights – If You Lost Money Investing in Soleno Therapeutics, Inc. Contact Robbins LLP for Information About Recovering Your Losses - GlobeNewsWire